Nurix Therapeutics, Inc.

Contributing Author

Recent Articles by Nurix Therapeutics, Inc.

Jul-07	European Medicines Agency Grants Bexobrutideg (NX-5948) Orphan Drug Designation for the Treatment of Lymphoplasmacytic Lymphoma, also Known as Waldenstrom Macroglobulinemia NRIX GlobeNewswire
Jun-13	Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NRIX GlobeNewswire
Jun-12	Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenstrom Macroglobulinemia (WM) NRIX GlobeNewswire
Jun-06	Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025) NRIX GlobeNewswire
Jun-02	Sanofi Exercises License Extension Option to Nurix's STAT6 Program NRIX GlobeNewswire
May-28	Nurix Therapeutics to Participate in the Jefferies Global Healthcare Conference NRIX GlobeNewswire
May-16	Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NRIX GlobeNewswire
May-15	Nurix Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference NRIX GlobeNewswire
May-14	Nurix Therapeutics Announces Presentations of Clinical Data at the 30th European Hematology Association Congress and the 18th International Conference on Malignant Lymphoma NRIX GlobeNewswire